Opko Health Inc. (NASDAQ:OPK) has been given an average rating of “Buy” by the eleven brokerages that are currently covering the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $15.69.
OPK has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Friday, March 3rd. Laidlaw reaffirmed a “buy” rating and set a $19.00 price objective (down from $22.00) on shares of Opko Health in a report on Tuesday, January 3rd. Standpoint Research reaffirmed a “buy” rating on shares of Opko Health in a report on Friday, December 30th. Guggenheim started coverage on shares of Opko Health in a report on Tuesday, March 14th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Jefferies Group LLC lowered their price target on shares of Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Thursday, March 2nd.
Shares of Opko Health (NASDAQ:OPK) opened at 8.00 on Tuesday. The firm has a 50-day moving average price of $8.28 and a 200-day moving average price of $9.62. Opko Health has a 12-month low of $7.13 and a 12-month high of $12.15. The firm’s market cap is $4.47 billion.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, March 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The company earned $275.50 million during the quarter, compared to the consensus estimate of $310.82 million. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities research analysts expect that Opko Health will post ($0.10) earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
In other news, CEO Phillip Md Et Al Frost acquired 20,000 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The shares were purchased at an average price of $9.04 per share, for a total transaction of $180,800.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $27,743,317.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Adam Logal sold 112,975 shares of the business’s stock in a transaction dated Tuesday, March 14th. The shares were sold at an average price of $8.07, for a total transaction of $911,708.25. Following the completion of the transaction, the insider now owns 234,996 shares in the company, valued at approximately $1,896,417.72. The disclosure for this sale can be found here. Insiders acquired 378,900 shares of company stock valued at $3,155,881 over the last three months. 40.74% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in OPK. Norges Bank purchased a new position in Opko Health during the fourth quarter worth about $30,421,000. State Street Corp boosted its position in Opko Health by 3.0% in the fourth quarter. State Street Corp now owns 7,787,875 shares of the company’s stock worth $72,427,000 after buying an additional 226,132 shares during the last quarter. Whalerock Point Partners LLC purchased a new position in Opko Health during the third quarter worth about $2,100,000. Piedmont Investment Advisors LLC purchased a new position in Opko Health during the third quarter worth about $622,000. Finally, Russell Investments Group Ltd. purchased a new position in Opko Health during the fourth quarter worth about $648,000. Hedge funds and other institutional investors own 22.58% of the company’s stock.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.